Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes evidence suggesting that smoking is associated with alopecia and premature hair graying, with smokers showing higher prevalence than nonsmokers.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study identified peripheral myeloid cells as the earliest dysregulated immune cells in PINK1 KO mice with Parkinson’s-like symptoms following intestinal infections, suggesting that PINK1 regulates gut immune functions linked to early Parkinson’s disease mechanisms.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

This review examined the psychological effects, mechanisms, health associations, and treatments related to premature hair graying, highlighting factors like genetics, oxidative stress, smoking, and diet, with the aim of enhancing understanding and addressing its broader implications.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This review of literature and market analysis found that rice bran extracts may promote hair growth through molecular mechanisms while being safe for cosmetic use, though further research is warranted.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study concluded that hair pigmentation, as measured by eumelanin-to-pheomelanin ratio, is not a risk factor for developing alopecia areata when compared to androgenetic alopecia patients.

This study found that scalp hair loss is the most bothersome symptom of alopecia areata for both adults and adolescents, highlighting the need for treatments focused on improving scalp hair growth.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

In this report, Biofibre® medical hair prosthetic fibers were shown to meet safety and biocompatibility standards, offering immediate aesthetic results for hair loss treatment with minor surgical intervention and reversible implantation, but requiring good after-care and yearly maintenance for optimal cosmetic outcomes.

This review of 32 articles suggests a stronger association between alopecia areata and allergic rhinitis than asthma in both adults and children, indicating a potential Th2-mediated component.

This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.

Exosome therapies could help with skin and hair issues, but more testing is needed.

This study concluded that noninvasive imaging techniques offer potential benefits in managing scalp conditions by potentially reducing the need for biopsies and minimizing patient morbidity, each technique having unique advantages and limitations for specific conditions.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This study reported that in Hispanic/Latinx patients with alopecia areata, rheumatoid arthritis was a common autoimmune comorbidity, and gastroesophageal reflux disease was notably more prevalent than in other populations with alopecia areata.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study found that coconut oil clinically helps with brittle hair and hair infestation, while evidence for castor and argan oils improving hair growth or quality is weak.

This review discusses the onset and characteristics of telogen effluvium following SARS-CoV-2 infection, implicating stress, cytokine release, or viral damage, and reports no new clinical results.

In this study, researchers observed that while there were no significant microvascular abnormalities in the macula of PCOS patients, the parafoveal thickness was significantly increased in most quadrants.

This review reports that botulinum toxin is used in dermatology not only for treating rhytides but also for conditions like rosacea, hyperhidrosis, and menopause-related flushing, although its full safety and efficacy profile requires more research.

This study found that a topical herbal solution significantly increased hair diameter and density in men with androgenetic alopecia compared to minoxidil after 36 weeks of treatment.